Amoxicillin/clavulanate potassium
ApprovedSmall molecule
Johnson & JohnsonAmoxicillin/clavulanate potassium is one of 123 small molecule programs targeting Bacterial Pneumonia. It is currently in Approved.
4
Indications
10
Total Trials
1
Active Trials
122
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
163 competitors in Urinary Tract Infection
#DrugCompanyPhaseTrials
1Maxipime
PfizerPhase 3
Medrol
PfizerPhase 3
Merrem
BB. Braun Medical Inc.
Phase 3
Rocephin
CConrado Roberto Hoffmann Filho
Phase 3
Decadron
AAspen Global Incorporated
Phase 3
Amoxicillin/clavulanate potassium
Johnson & JohnsonApproved
Piperacillin/tazobactam
PfizerPhase 3
Prulifloxacin
Merck & Co.Phase 3
Blujepa
GGlaxo Dba Glaxosmithkline
Phase 3
Amoxicillin/clavulanate
BayerPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Bacterial Pneumonia1 trial
Pulmonary TB1 trial
Preoperative1 trial
Effect of Preoperative Amoxicillin/Clavulanic Acid Combination on Postoperative Endodontic Pain
Completed·—·N/A·NCT03033147·72 enrolled
5 more indications
Pain1 trial
Effect of Amoxicillin/Clavulanic Acid Combination on Postoperative Endodontic Pain
Unknown status·—·N/A·NCT03007342·78 enrolled
Complicated Intra-abdominal Infections1 trial
Urinary Tract Infection1 trial
Adolescent1 trial
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company